2013 was the best year for the US IPO market since 2000. Against a favorable backdrop marked by a rising stock market, low interest rates, reduced volatility and increased risk tolerance among investors, a total of 222 companies went public and raised $55...read more
For the fifth consecutive week, at least one US IPO gained 30%, as Gigamon (GIMO) climbed nearly 50%. The week's most prominent IPO, Coty (COTY), faltered though, and the third scheduled deal, Aratana Therapeutics (PETX) was delayed. Nine more IPOs,...read more
Coty, a fragrance and cosmetics company with several globally recognized brands, raised $1.0 billion by offering 57.1 million shares at $17.50, within the range of $16.50 to $18.50. Coty plans to list on the NYSE under the symbol COTY. BofA Merrill Lynch, J.P....read more
Renaissance Capital's 2013 US IPO Annual Review
2013 was the best year for the US IPO market since 2000. Against a favorable backdrop marked by a rising stock market, low interest rates, reduced volatility and increased risk tolerance among investors, a total of 222 companies went public and raised $55...read more
US IPO Recap: Coty fades, Gigamon springs and 17 companies file or set terms
For the fifth consecutive week, at least one US IPO gained 30%, as Gigamon (GIMO) climbed nearly 50%. The week's most prominent IPO, Coty (COTY), faltered though, and the third scheduled deal, Aratana Therapeutics (PETX) was delayed. Nine more IPOs,...read more
Coty prices IPO at $17.50, within the range
Coty, a fragrance and cosmetics company with several globally recognized brands, raised $1.0 billion by offering 57.1 million shares at $17.50, within the range of $16.50 to $18.50. Coty plans to list on the NYSE under the symbol COTY. BofA Merrill Lynch, J.P....read more
3 US IPOs planned for the week of Jun 10
The following IPOs are expected to price this week:
Aratana Therapeutics (PETX), which is developing medications for cats and dogs based on therapies for human,...read more